ClinicalTrials.gg
CompletedNCT07022379REMOTE-HFUpdated Mar 25, 2026

Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program

An observational study in Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart Failure With Reduced Ejection Fraction, sponsored by Satelia. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Satelia · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
13,660
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.

Enrollment
10th of 161
13,660 · median 321
Started
2021
with 20 others
Observational
161 of 448
28 open now
Registered
404th of 448
by date

Among the 448 studies in Heart Failure with a site in France, this one is the 10th largest by enrollment of the 161 observational ones that give a count, is one of 21 that started in 2021, is one of 161 observational ones, and was the 404th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Heart Failure with a site in France, or all of them as a file.
02

Study summary

This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring program in France between 2021 and 2024. The analysis examines SGLT2i use at the time of enrollment in relation to left ventricular ejection fraction subgroups and evolving scientific evidence, including major clinical trial publications and guideline updates. Demographic, clinical, and healthcare setting factors associated with SGLT2i prescription in routine clinical practice are assessed using retrospective data from the remote monitoring program database. No study-mandated interventions were performed, and all treatments were prescribed as part of usual care.

Read the detailed description

This retrospective, multicenter observational cohort study was conducted in France between January 1, 2021 and December 31, 2024 within a nationwide heart failure (HF) remote monitoring program. The study included adult patients with chronic heart failure enrolled in the program following hospitalization for HF or in the ambulatory setting with elevated natriuretic peptide levels.

The remote monitoring program supports routine HF management using a digital platform that enables structured follow-up and communication between patients and healthcare providers. Clinical and treatment data recorded at the time of enrollment were extracted from the program database for analysis.

The primary objective of the study is to describe the prevalence of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use at enrollment. Secondary objectives include evaluation of temporal trends in SGLT2i prescriptions across predefined time periods corresponding to major clinical trial publications and guideline updates, and identification of demographic, clinical, and healthcare setting factors associated with SGLT2i use.

Analyses focus on medication use as part of routine clinical care. No study-specific interventions were assigned, and all treatments were prescribed at the discretion of the treating clinicians. Statistical analyses include descriptive methods and multivariable regression modeling to assess factors independently associated with SGLT2i prescription.

03

Conditions studied

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Browse trials for

Keywords

  • Sodium-glucose cotransporter 2 inhibitors
  • Guideline-directed medical therapy
  • Telemonitoring
  • Remote patient monitoring
  • Chronic heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adults with chronic heart failure in France who were enrolled in a nationwide remote patient monitoring program between January 2021 and December 2024 as part of routine clinical care. Enrollment typically followed hospitalization for heart failure or occurred in ambulatory patients with elevated natriuretic peptide levels consistent with heart failure management guidelines. The cohort represents patients managed across a range of healthcare settings, including university hospitals, non-university hospitals, and outpatient practices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of chronic heart failure
  • Enrolment in the national heart failure remote monitoring program between January 2021 and December 2024
  • Enrolment following hospitalization for heart failure or in the ambulatory setting with elevated natriuretic peptide levels consistent with program eligibility criteria

Exclusion criteria

Exclusion Criteria:

- Missing baseline medication data at the time of program enrolment

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
13,660 participants (actual)
Patient registry
No

Groups and cohorts

  • Heart Failure Remote Monitoring Cohort

    Adults with chronic heart failure enrolled in a nationwide remote patient monitoring program in France between January 2021 and December 2024. Clinical and treatment data at the time of enrollment were analyzed to evaluate patterns of sodium-glucose cotransporter 2 inhibitor use in routine care.

    Other: SGLT2 Inhibitor Use

Interventions

  • OtherSGLT2 Inhibitor Use

    Prescription of a sodium-glucose cotransporter 2 inhibitor as part of routine clinical care at the time of enrollment in the remote monitoring program. Treatment decisions were made by the treating physician and were not study-mandated.

06

What researchers measure

Primary outcomes

  1. Prevalence of SGLT2 Inhibitor Use at Enrolment

    Proportion of patients with chronic heart failure who were prescribed a sodium-glucose cotransporter 2 inhibitor as part of routine clinical care at the time of enrolment in the remote monitoring program.

    Time frame: Prescription at time of enrolment into the remote monitoring program (baseline)

Secondary outcomes

  1. Temporal Trends in SGLT2 Inhibitor Use

    Changes in the prevalence of SGLT2 inhibitor prescription over time according to study periods corresponding to major clinical trial publications and guideline updates.

    Time frame: Across four predefined study periods between January 2021 and December 2024

  2. Clinical and Healthcare Setting Factors Associated With SGLT2 Inhibitor Use

    Association between demographic, clinical, and healthcare setting characteristics and likelihood of SGLT2 inhibitor prescription, assessed using multivariable regression analysis.

    Time frame: At time of enrollment (baseline)

07

Study locations

1 site
  • NP Medical
    Bordeaux, 33000, France
08

References and documents

Publications

  • Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. PubMed 36027570 ↗
  • McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. PubMed 31535829 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195. No abstract available. PubMed 37622666 ↗
  • Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. PubMed 32865377 ↗
  • Monzo L, Hanon O, Savarese G, Fauvel C, Berthelot E, Seronde MF, Assyag P, Esser R, Picard F, Pages N, Nisse-Durgeat S, Girerd N. Temporal trends and factors associated with SGLT2 inhibitor prescription in a nationwide French heart failure remote monitoring program. Int J Cardiol. 2026 Jul 21:134683. doi: 10.1016/j.ijcard.2026.134683. Online ahead of print. PubMed 42480823 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2024, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Jan 1, 2021
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07022379
Lead sponsor
Satelia
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jan 1, 2021
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Mar 25, 2026

Study contacts

Nicolas Girerd, PhD, MD
principal investigator · CHRU Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion